Short Interest in Precipio, Inc. (NASDAQ:PRPO) Expands By 22.5%

Precipio, Inc. (NASDAQ:PRPO) was the target of a large growth in short interest in the month of January. As of January 30th, there was short interest totaling 4,048 shares, a growth of 22.5% from the January 15th total of 3,304 shares. Currently, 0.3% of the shares of the company are short sold. Based on an average daily trading volume, of 10,844 shares, the short-interest ratio is presently 0.4 days. Based on an average daily trading volume, of 10,844 shares, the short-interest ratio is presently 0.4 days. Currently, 0.3% of the shares of the company are short sold.

Institutional Trading of Precipio

Institutional investors and hedge funds have recently modified their holdings of the stock. Susquehanna International Group LLP purchased a new position in shares of Precipio during the third quarter valued at approximately $194,000. Renaissance Technologies LLC boosted its position in Precipio by 10.7% during the fourth quarter. Renaissance Technologies LLC now owns 14,500 shares of the biotechnology company’s stock worth $333,000 after purchasing an additional 1,400 shares during the period. Geode Capital Management LLC increased its stake in shares of Precipio by 5.1% in the fourth quarter. Geode Capital Management LLC now owns 16,388 shares of the biotechnology company’s stock worth $377,000 after purchasing an additional 789 shares in the last quarter. Evernest Financial Advisors LLC purchased a new position in shares of Precipio in the third quarter worth about $374,000. Finally, Topline Capital Management LLC bought a new stake in shares of Precipio in the third quarter valued at approximately $1,158,000. 10.45% of the stock is owned by hedge funds and other institutional investors.

Precipio Trading Up 0.5%

Shares of PRPO stock opened at $23.50 on Wednesday. Precipio has a twelve month low of $3.90 and a twelve month high of $28.50. The stock’s fifty day simple moving average is $23.55 and its 200 day simple moving average is $20.64. The company has a quick ratio of 1.10, a current ratio of 1.27 and a debt-to-equity ratio of 0.06. The firm has a market capitalization of $41.13 million, a P/E ratio of -28.66 and a beta of 1.20.

Wall Street Analyst Weigh In

A number of analysts have issued reports on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Precipio in a report on Thursday, January 22nd. Wall Street Zen upgraded shares of Precipio to a “hold” rating in a research report on Saturday. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has an average rating of “Sell”.

About Precipio

Precipio, Inc is a clinical-stage diagnostics and medical technology company focused on advancing the detection and management of hematologic diseases. The firm develops precision diagnostic solutions that integrate digital morphology, immunophenotyping, and molecular testing to improve the diagnosis of leukemia and related blood disorders. Precipio’s approach is designed to enhance the accuracy and speed of laboratory workflows, helping physicians tailor treatment strategies more effectively.

The company’s core offerings include an automated digital imaging and analysis platform that captures and classifies blood and bone marrow cell images at high throughput.